SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G
INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO
RULE 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED
PURSUANT TO RULE 13d-2
(Amendment No. 4)
Harpoon Therapeutics, Inc.
(Name of Issuer)
Common Stock, $0.0001 par value per share
(Title of Class of Securities)
41358P106
(CUSIP Number)
March 23, 2023
(Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
☐ Rule 13d-1(b)
☒ Rule 13d-1(c)
☐ Rule 13d-1(d)
| (1) | The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page. |
The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).
| CUSIP No. 41358P106 | Page 2 of 12 Pages |
| 1 | NAMES OF REPORTING PERSONS I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)
New Leaf Ventures III, L.P. (“NLV III”) | |||||
| 2 | CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS) (a) ☐ (b) ☒
| |||||
| 3 | SEC USE ONLY
| |||||
| 4 | CITIZENSHIP OR PLACE OF ORGANIZATION
Delaware | |||||
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH | 5 | SOLE VOTING POWER
0 | ||||
| 6 | SHARED VOTING POWER
2,242,839 (1) | |||||
| 7 | SOLE DISPOSITIVE POWER
0 | |||||
| 8 | SHARED DISPOSITIVE POWER
2,242,839 (1) | |||||
| 9 | AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
2,242,839 (1) | |||||
| 10 | CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
☐ | |||||
| 11 | PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
6.0% (2) | |||||
| 12 | TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
PN | |||||
| (1) | All of such shares are Common Stock and held of record by NLV III. New Leaf Venture Associates III, L.P. (“NLVA III”) is the general partner of NLV III and may be deemed to have voting, investment and dispositive power with respect to these securities. New Leaf Venture Management III, L.L.C. (“NLV Management III”) is the sole general partner of NLVA III and ultimate general partner of NLV III and may be deemed to have voting, investment and dispositive power with respect to these securities. Each of Ronald M. Hunt (“Hunt”) and Vijay K. Lathi (“Lathi”) are the Managing Directors of NLV Management III (collectively, the “NLV Managing Directors”). Each of the NLV Managing Directors, may be deemed to have shared voting, investment and dispositive power with respect to these securities. |
| (2) | Based on 37,447,535 shares of Common Stock outstanding as of February 28, 2023, as reported in the Issuer’s Quarterly Report on Form 10-K for the year ended December 31, 2022, as filed with the United States Securities and Exchange Commission on March 27, 2023 (the “Form 10-K”). |
| CUSIP No. 41358P106 | Page 3 of 12 Pages |
| 1 | NAMES OF REPORTING PERSONS I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)
New Leaf Venture Associates III, L.P. | |||||
| 2 | CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS) (a) ☐ (b) ☒
| |||||
| 3 | SEC USE ONLY
| |||||
| 4 | CITIZENSHIP OR PLACE OF ORGANIZATION
Delaware | |||||
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH | 5 | SOLE VOTING POWER
0 | ||||
| 6 | SHARED VOTING POWER
2,242,839 (1) | |||||
| 7 | SOLE DISPOSITIVE POWER
0 | |||||
| 8 | SHARED DISPOSITIVE POWER
2,242,839 (1) | |||||
| 9 | AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
2,242,839 (1) | |||||
| 10 | CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
☐ | |||||
| 11 | PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
6.0% (2) | |||||
| 12 | TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
PN | |||||
| (1) | All of such shares are Common Stock and held of record by NLV III. NLVA III is the general partner of NLV III and may be deemed to have voting, investment and dispositive power with respect to these securities. NLV Management III is the sole general partner of NLVA III and ultimate general partner of NLV III and may be deemed to have voting, investment and dispositive power with respect to these securities. Each of the NLV Managing Directors may be deemed to have shared voting, investment and dispositive power with respect to these securities. |
| (2) | Based on 37,447,535 shares of Common Stock outstanding as of February 28, 2023, as reported in the Issuer’s Form 10-K. |
| CUSIP No. 41358P106 | Page 4 of 12 Pages |
| 1 | NAMES OF REPORTING PERSONS I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)
New Leaf Venture Management III, L.L.C. | |||||
| 2 | CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS) (a) ☐ (b) ☒
| |||||
| 3 | SEC USE ONLY
| |||||
| 4 | CITIZENSHIP OR PLACE OF ORGANIZATION
Delaware | |||||
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH | 5 | SOLE VOTING POWER
0 | ||||
| 6 | SHARED VOTING POWER
2,242,839 (1) | |||||
| 7 | SOLE DISPOSITIVE POWER
0 | |||||
| 8 | SHARED DISPOSITIVE POWER
2,242,839 (1) | |||||
| 9 | AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
2,242,839 (1) | |||||
| 10 | CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
☐ | |||||
| 11 | PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
6.0% (2) | |||||
| 12 | TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
OO | |||||
| (1) | All of such shares are Common Stock and held of record by NLV III. NLVA III is the general partner of NLV III and may be deemed to have voting, investment and dispositive power with respect to these securities. NLV Management III is the sole general partner of NLVA III and ultimate general partner of NLV III and may be deemed to have voting, investment and dispositive power with respect to these securities. Each of the NLV Managing Directors may be deemed to have shared voting, investment and dispositive power with respect to these securities. |
| (2) | Based on 37,447,535 shares of Common Stock outstanding as of February 28, 2023, as reported in the Issuer’s Form 10-K. |
| CUSIP No. 41358P106 | Page 5 of 12 Pages |
| 1 | NAMES OF REPORTING PERSONS I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)
New Leaf Biopharma Opportunities II, L.P. (“Biopharma II”) | |||||
| 2 | CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS) (a) ☐ (b) ☒
| |||||
| 3 | SEC USE ONLY
| |||||
| 4 | CITIZENSHIP OR PLACE OF ORGANIZATION
Delaware | |||||
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH | 5 | SOLE VOTING POWER
0 | ||||
| 6 | SHARED VOTING POWER
3,908,165 (1)(2) | |||||
| 7 | SOLE DISPOSITIVE POWER
0 | |||||
| 8 | SHARED DISPOSITIVE POWER
3,908,165 (1)(2) | |||||
| 9 | AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
3,908,165 (1)(2) | |||||
| 10 | CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
☐ | |||||
| 11 | PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
9.7% (3) | |||||
| 12 | TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
PN | |||||
| (1) | All such shares are held of record by Biopharma II. New Leaf BPO Associates II, L.P. (“NLBA II”) is the general partner of Biopharma II and may be deemed to have voting, investment and dispositive power with respect to these securities. New Leaf BPO Management II, L.L.C. (“NLB Management II”) is the sole general partner of NLBA II and ultimate general partner of Biopharma II and may be deemed to have voting, investment and dispositive power with respect to these securities. Hunt and Lathi are the managing directors of NLB Management II (collectively, the “NLB Managing Directors”). Each of the NLB Managing Directors may be deemed to have shared voting, investment and dispositive power with respect to these securities. |
| (2) | Includes (i) 913,860 shares of Common Stock, and (ii) 2,994,305 shares of Common Stock underlying warrants that are exercisable immediately. Such amount excludes 10,000 shares of the Issuer’s 8.000% Series A Redeemable Preferred Stock which is non-voting and does not convert into Common Stock. |
| (3) | Based on 37,447,535 shares of Common Stock outstanding as of February 28, 2023, as reported in the Issuer’s Form 10-K, plus 2,994,305 shares of Common Stock underlying warrants that are exercisable immediately. |
| CUSIP No. 41358P106 | Page 6 of 12 Pages |
| 1 | NAMES OF REPORTING PERSONS I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)
New Leaf BPO Associates II, L.P. | |||||
| 2 | CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS) (a) ☐ (b) ☒
| |||||
| 3 | SEC USE ONLY
| |||||
| 4 | CITIZENSHIP OR PLACE OF ORGANIZATION
Delaware | |||||
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH | 5 | SOLE VOTING POWER
0 | ||||
| 6 | SHARED VOTING POWER
3,908,165 (1)(2) | |||||
| 7 | SOLE DISPOSITIVE POWER
0 | |||||
| 8 | SHARED DISPOSITIVE POWER
3,908,165 (1)(2) | |||||
| 9 | AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
3,908,165(1)(2) | |||||
| 10 | CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
☐ | |||||
| 11 | PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
9.7% (3) | |||||
| 12 | TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
PN | |||||
| (1) | All such shares are held of record by Biopharma II. NLBA II is the general partner of Biopharma II and may be deemed to have voting, investment and dispositive power with respect to these securities. NLB Management II is the sole general partner of NLBA II and ultimate general partner of Biopharma II and may be deemed to have voting, investment and dispositive power with respect to these securities. Each of the NLB Managing Directors may be deemed to have shared voting, investment and dispositive power with respect to these securities. |
| (2) | Includes (i) 913,860 shares of Common Stock, and (ii) 2,994,305 shares of Common Stock underlying warrants that are exercisable immediately. Such amount excludes 10,000 shares of the Issuer’s 8.000% Series A Redeemable Preferred Stock which is non-voting and does not convert into Common Stock. |
| (3) | Based on 37,447,535 shares of Common Stock outstanding as of February 28, 2023, as reported in the Issuer’s Form 10-K, plus 2,994,305 shares of Common Stock underlying warrants that are exercisable immediately. |
| CUSIP No. 41358P106 | Page 7 of 12 Pages |
| 1 | NAMES OF REPORTING PERSONS I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)
New Leaf BPO Management II, L.L.C. | |||||
| 2 | CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS) (a) ☐ (b) ☒
| |||||
| 3 | SEC USE ONLY
| |||||
| 4 | CITIZENSHIP OR PLACE OF ORGANIZATION
Delaware | |||||
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH | 5 | SOLE VOTING POWER
0 | ||||
| 6 | SHARED VOTING POWER
3,908,165 (1)(2) | |||||
| 7 | SOLE DISPOSITIVE POWER
0 | |||||
| 8 | SHARED DISPOSITIVE POWER
3,908,165 (1)(2) | |||||
| 9 | AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
3,908,165 (1)(2) | |||||
| 10 | CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
☐ | |||||
| 11 | PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
9.7% (3) | |||||
| 12 | TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
OO | |||||
| (1) | All such shares are held of record by Biopharma II. NLBA II is the general partner of Biopharma II and may be deemed to have voting, investment and dispositive power with respect to these securities. NLB Management II is the sole general partner of NLBA II and ultimate general partner of Biopharma II and may be deemed to have voting, investment and dispositive power with respect to these securities. Each of the NLB Managing Directors may be deemed to have shared voting, investment and dispositive power with respect to these securities. |
| (2) | Includes (i) 913,860 shares of Common Stock, and (ii) 2,994,305 shares of Common Stock underlying warrants that are exercisable immediately. Such amount excludes 10,000 shares of the Issuer’s 8.000% Series A Redeemable Preferred Stock which is non-voting and does not convert into Common Stock. |
| (3) | Based on 37,447,535 shares of Common Stock outstanding as of February 28, 2023, as reported in the Issuer’s Form 10-K, plus 2,994,305 shares of Common Stock underlying warrants that are exercisable immediately. |
| CUSIP No. 41358P106 | Page 8 of 12 Pages |
| 1 | NAMES OF REPORTING PERSONS I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)
Ronald M. Hunt | |||||
| 2 | CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS) (a) ☐ (b) ☒
| |||||
| 3 | SEC USE ONLY
| |||||
| 4 | CITIZENSHIP OR PLACE OF ORGANIZATION
United States | |||||
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH | 5 | SOLE VOTING POWER
97,465 shares of Common Stock underlying fully vested stock options owned directly by Hunt. | ||||
| 6 | SHARED VOTING POWER
6,151,004 (1)(2) | |||||
| 7 | SOLE DISPOSITIVE POWER
97,465 shares of Common Stock underlying fully vested stock options owned directly by Hunt. | |||||
| 8 | SHARED DISPOSITIVE POWER
6,151,004 (1)(2) | |||||
| 9 | AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
6,248,469 (3) | |||||
| 10 | CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
☐ | |||||
| 11 | PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
15.4% (4) | |||||
| 12 | TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
IN | |||||
| (1) | 2,242,839 of such shares are held of record by NLV III. NLVA III is the general partner of NLV III and may be deemed to have voting, investment and dispositive power with respect to these securities. NLV Management III is the sole general partner of NLVA III and ultimate general partner of NLV III and may be deemed to have voting, investment and dispositive power with respect to these securities. Each of the NLV Managing Directors may be deemed to have shared voting, investment and dispositive power with respect to these securities. 3,908,165 of such shares are held of record by Biopharma II. NLBA II is the general partner of Biopharma II and may be deemed to have voting, investment and dispositive power with respect to these securities. NLB Management II is the sole general partner of NLBA II and ultimate general partner of Biopharma II and may be deemed to have voting, investment and dispositive power with respect to these securities. Each of the NLB Managing Directors may be deemed to have shared voting, investment and dispositive power with respect to these securities. |
| (2) | The 3,908,165 shares held by Biopharma II include (i) 913,860 shares of Common Stock, and (ii) 2,994,305 shares of Common Stock underlying warrants that are exercisable immediately. Such amount excludes 10,000 shares of the Issuer’s 8.000% Series A Redeemable Preferred Stock which is non-voting and does not convert into Common Stock. |
| (3) | Consists of (i) 2,242,839 shares held of record by NLV III, (ii) 3,908,165 shares held of record by Biopharma II, of which (a) 913,860 of such shares are shares of Common Stock, and (b) 2,994,305 of such shares represent shares of Common Stock underlying warrants that are exercisable immediately, and (iii) 97,465 shares of Common Stock underlying fully vested stock options granted to Hunt in his capacity as a member of the Issuer’s board of directors. |
| (4) | Based on 40,539,305 shares of Common Stock, calculated as follows (i) 37,447,535 shares of Common Stock outstanding as of February 28, 2023, as reported in the Issuer’s Form 10-K plus (ii) (a) 97,465 shares of Common Stock underlying fully vested stock options granted to Hunt in his capacity as a member of the Issuer’s board of directors, and (b) 2,994,305 shares of Common Stock underlying warrants issued to Biopharma II that are immediately exercisable. |
| CUSIP No. 41358P106 | Page 9 of 12 Pages |
| 1 | NAMES OF REPORTING PERSONS I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)
Vijay K. Lathi | |||||
| 2 | CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS) (a) ☐ (b) ☒
| |||||
| 3 | SEC USE ONLY
| |||||
| 4 | CITIZENSHIP OR PLACE OF ORGANIZATION
United States | |||||
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH | 5 | SOLE VOTING POWER
0 | ||||
| 6 | SHARED VOTING POWER
6,151,004 (1)(2) | |||||
| 7 | SOLE DISPOSITIVE POWER
0 | |||||
| 8 | SHARED DISPOSITIVE POWER
6,151,004 (1)(2) | |||||
| 9 | AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
6,151,004 (1)(2) | |||||
| 10 | CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
☐ | |||||
| 11 | PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
15.2% (3) | |||||
| 12 | TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
IN | |||||
| (1) | 2,242,839 of such shares are held of record by NLV III. NLVA III is the general partner of NLV III and may be deemed to have voting, investment and dispositive power with respect to these securities. NLV Management III is the sole general partner of NLVA III and ultimate general partner of NLV III and may be deemed to have voting, investment and dispositive power with respect to these securities. Each of the NLV Managing Directors, may be deemed to have shared voting, investment and dispositive power with respect to these securities. 3,908,165 of such shares are held of record by Biopharma II. NLBA II is the general partner of Biopharma II and may be deemed to have voting, investment and dispositive power with respect to these securities. NLB Management II is the sole general partner of NLBA II and ultimate general partner of Biopharma II and may be deemed to have voting, investment and dispositive power with respect to these securities. Each of the NLB Managing Directors may be deemed to have shared voting, investment and dispositive power with respect to these securities. |
| (2) | The 3,908,165 shares held by Biopharma II include (i) 913,860 shares of Common Stock, and (ii) 2,994,305 shares of Common Stock underlying warrants that are exercisable immediately. Such amount excludes 10,000 shares of the Issuer’s 8.000% Series A Redeemable Preferred Stock which is non-voting and does not convert into Common Stock. |
| (2) | Based on 37,447,535 shares of Common Stock outstanding as of February 28, 2023, as reported in the Issuer’s Form 10-K, plus 2,994,305 shares of Common Stock underlying warrants that are exercisable immediately that are held by Biopharma II. |
| CUSIP No. 41358P106 | Page 10 of 12 Pages |
Schedule 13G
This Amendment No. 4 (“Amendment”) amends and supplements the Schedule 13G originally filed with the United States Securities and Exchange Commission (the “SEC”) on February 21, 2019, as amended by Amendment No. 1 filed with the SEC on February 13, 2020, Amendment No. 2 filed with the SEC on February 11, 2022 and Amendment No. 3 filed with the SEC on February 6, 2023 (collectively, the “Original Schedule 13G”), by New Leaf Ventures III, L.P. (“NLV III”), New Leaf Venture Associates III, L.P. (“NLVA III”), New Leaf Venture Management III, L.L.C. (“NLV Management III”), New Leaf Biopharma Opportunities II, L.P. (“Biopharma II”), New Leaf BPO Associates II, L.P. (“NLBA II”), New Leaf BPO Management II, L.L.C. (“NLB Management II” and together with NLV III, NLVA III, NLV Management III, Biopharma II and NLBA II, the “Reporting Entities”), Ronald M. Hunt, a member of the Issuer’s board of directors (“Hunt”), and Vijay K. Lathi (“Lathi” and, together with Hunt, the “Reporting Individuals”). The Reporting Entities and the Reporting Individuals collectively are referred to as the “Reporting Persons”. Hunt and Lathi are the (i) managing directors of NLV Management III (collectively, the “NLV Managing Directors”) and (ii) managing directors of NLB Management II (collectively, the “NLB Managing Directors”). Only those items that are hereby reported are amended; all other items reported in the Original Schedule 13G remain unchanged. Information given in response to each item shall be deemed incorporated by reference in all other items, as applicable. Capitalized terms not defined in this Amendment have the meanings ascribed to them in the Original Schedule 13G.
Item 2(b). Address or principal business office.
The principal business office of each of the Reporting Persons is 156 Fifth Avenue, Suite 820, New York, NY 10010.
Item 4. Ownership.
| (a) | Amount beneficially owned: |
See line 9 of cover sheets.
| (b) | Percent of class: |
See Line 11 and the corresponding footnotes on each of the cover sheets.
| (c) | Number of shares as to which the person has: |
| (i) | Sole power to vote or to direct the vote: see line 5 of cover sheets.* |
| (ii) | Shared power to vote or to direct the vote: see line 6 of cover sheets.* |
| (iii) | Sole power to dispose or to direct the disposition of: see line 7 of cover sheets.* |
| (iv) | Shared power to dispose or to direct the disposition of: see line 8 of cover sheets.* |
| * | Each Reporting Person disclaims beneficial ownership of such shares, except for the shares, if any, such Reporting Person holds of record and to the extent of its pecuniary interest therein. |
| CUSIP No. 41358P106 | Page 11 of 12 Pages |
SIGNATURES
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
Date: March 30, 2023
NEW LEAF VENTURES III, L.P. | ||||||
By: | NEW LEAF VENTURE ASSOCIATES III, L.P. | |||||
Its General Partner | ||||||
By: | NEW LEAF VENTURE MANAGEMENT III, L.L.C. | |||||
Its General Partner | ||||||
By: | /s/ Craig L. Slutzkin | |||||
Craig L. Slutzkin | ||||||
Chief Financial Officer | ||||||
NEW LEAF VENTURE ASSOCIATES III, L.P. | ||||||
By: | NEW LEAF VENTURE MANAGEMENT III, L.L.C. | |||||
Its General Partner | ||||||
By: | /s/ Craig L. Slutzkin | |||||
Craig L. Slutzkin | ||||||
Chief Financial Officer | ||||||
NEW LEAF VENTURE MANAGEMENT III, L.L.C. | ||||||
By: | /s/ Craig L. Slutzkin | |||||
Craig L. Slutzkin Chief Financial Officer | ||||||
NEW LEAF BIOPHARMA OPPORTUNITIES II, L.P. | ||||||
By: | NEW LEAF BPO ASSOCIATES II, L.P. | |||||
Its General Partner | ||||||
By: | NEW LEAF BPO MANAGEMENT II, L.L.C. | |||||
Its General Partner | ||||||
By: | /s/ Craig L. Slutzkin | |||||
Craig L. Slutzkin | ||||||
Chief Financial Officer | ||||||
| CUSIP No. 41358P106 | Page 12 of 12 Pages |
NEW LEAF BPO ASSOCIATES II, L.P. | ||
By: | NEW LEAF BPO MANAGEMENT II, L.L.C. | |
Its General Partner | ||
By: | /s/ Craig L. Slutzkin | |
Craig L. Slutzkin | ||
Chief Financial Officer | ||
NEW LEAF BPO MANAGEMENT II, L.L.C. | ||
By: | /s/ Craig L. Slutzkin | |
Craig L. Slutzkin | ||
Chief Financial Officer | ||
* | ||
Vijay K. Lathi | ||
* | ||
Ronald M. Hunt | ||
/s/ Craig L. Slutzkin |
* Craig L. Slutzkin |
As attorney-in-fact |
| * | This Schedule 13G was executed by Craig L. Slutzkin on behalf of the individuals listed above pursuant to Powers of Attorney. Note that copies of the applicable Powers of Attorney are already on file with the appropriate agencies. |
